ClinicalTrials.gg
CompletedNCT00707057Updated Mar 24, 2011Results posted

Ibuprofen Extended-Release Dental Pain Study

A Phase 3 interventional study of Ibuprofen 600 mg Extended-Release Tablets and Placebo in Pain, Post-Operative Pain and Third Molar Extraction, sponsored by SCOLR Pharma, Inc.. Completed at 1 site in United States. Open to participants aged 16 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-03-24.

Primary conditionPain, PostoperativeRegistry: PainReclassifiedWhy we changed it
Registry
Pain — the first condition term the registry derived for this study.
ClinicalTrials.gg
Pain, Postoperative
Why
  1. The study's listed conditions name Pain, Postoperative, a narrower term within Pain.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by SCOLR Pharma, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
256
Allocation
Randomized
Ages
16 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 56 studies testing ibuprofen in Pain, Postoperative — 7 open to participants now, 8 under way, none of them phase 3. Ibuprofen · Pain, Postoperative.

Enrollment
8th of 56
256 · median 100
Started
2008
the only one that year
Phase 3
7 of 56
none open now
Registered
2nd of 56
by date

Among the 56 studies testing ibuprofen in Pain, Postoperative, this one is the 8th largest by enrollment, is the only one that started in 2008, is one of 7 in phase 3, and was the 2nd registered.

Pain, Postoperative

5,671 studies on the registry are indexed under Pain, Postoperative; 1,241 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

7 of the 56 studies testing ibuprofen in Pain, Postoperative are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About ibuprofen

Ibuprofen: first FDA approval 1974 (MOTRIN), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 677 Pain, Postoperative studies recruiting now, 240 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 16 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies testing ibuprofen in Pain, Postoperative, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of multiple doses of Ibuprofen 600 mg Extended-Release Tablets in a study of dental pain following extraction of third molar teeth.

Read the detailed description

This is a single-center, multiple-dose, randomized, placebo-controlled, double-blinded, parallel group trial to evaluate the efficacy and safety of multiple doses of Ibuprofen 600 mg Extended-Release Tablets in a study of dental pain following extraction of third molar teeth. The surgery will consist of surgical extraction of 1-2 impacted third molars, of which one must be a mandibular impaction that is partially impacted in either tissue or bone. Subjects will be stratified according to baseline pain intensity, as rated on an 11-point pain intensity numerical rating scale (PI-NRS)and gender.

03

Conditions studied

  • Pain
  • Post-Operative Pain
  • Third Molar Extraction

Browse trials for

04

In context

Pain, Postoperative Reclassified

5,671 studies on the registry are indexed under Pain, Postoperative; 1,241 are open to participants now.

This study's enrollment of 256 is above the median of 75 across 4,850 interventional studies indexed under Pain, Postoperative.

Browse Pain, Postoperative studies →

Lead sponsor

This is the only study on the registry with SCOLR Pharma, Inc. as lead sponsor.

Compared within Pain, Postoperative, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Pain. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
16 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females 16 to 45 years of age;
  • Outpatients scheduled to undergo surgical extraction of 1-2 impacted third molar(s), one of which must be a mandibular impaction that is partially impacted in either tissue or bone;
  • At least a score of 5 on the 11-point pain intensity numerical rating scale (PI-NRS) at baseline;
  • Use of only the following preoperative medication(s) / anesthetic(s): short-acting local anesthetic (e.g., mepivacaine or lidocaine) with or without vasoconstrictor and/or nitrous oxide;
  • Reliable, cooperative, and adequate intelligence to record the requested information on the analgesic questionnaire form;
  • Subjects (or the parent or legal guardian of subjects under the age of 18 years) are required to read, comprehend, and sign the . Subjects requiring a parent or legal guardian to sign the informed consent will be required to sign an assent;
  • Examined by the attending dentist or physician and medically cleared to participate in the study; and,
  • In general good health and have no to any of the study meds.

Exclusion criteria

Exclusion Criteria:

  • Presence of a serious medical condition (e.g., poorly controlled hypertension, poorly controlled diabetes, significantly impaired cardiac, renal or hepatic function, hyper- or hypothyroidism);
  • Use of a prescription or nonprescription drug with which the administration of ibuprofen, celecoxib, any other non-steroidal anti-inflammatory drug (NSAID), or acetaminophen, is ;
  • Acute local infection at the time of surgery that could confound the post-surgical evaluation;
  • Females who are pregnant, lactating, of , or for less than 2 years and not using a medically approved method of (i.e., oral, transdermal, or implanted contraceptives, intrauterine device, diaphragm, condom, abstinence, or surgical sterility), or females who test positive on a urine-based pregnancy test;
  • Presence or history (within 2 years of enrollment) of bleeding disorder(s) or peptic ulcer disease;
  • Presence or history (within the past year) of alcoholism or substance abuse. Subjects who are taking CNS or other psychotropic drugs (including St. John's Wort, or any other nutritional supplement known to have psychotropic effects) may be enrolled if they have been on stable doses of medication for at least 2 months, will maintain this dose throughout the study, and their condition is judged by the Principal Investigator to be well-controlled;
  • Habituation to analgesic drugs (i.e., routine use of oral analgesics 5 or more times per week);
  • History of allergic reaction (eg, asthma, rhinitis, swelling, shock, or hives) to ibuprofen, naproxen, aspirin, celecoxib, any other NSAID, or acetaminophen;
  • Prior use of any type of analgesic or NSAID 5 half-lives of that drug or less before taking the first dose of study medication, except for pre-anesthetic medication and anesthesia for the procedure;
  • Ingestion of any caffeine-containing beverages, chocolate, or alcohol 4 hours or less before taking the first dose of study medication;
  • Has taken an product within the past 30 days;
  • Has previously been entered into this study; and,
  • The subject is a member of the study site staff either directly involved with the study, an employee of the Sponsor, or a relative of study site personnel directly involved with the study or Sponsor.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
256 participants (actual)

Study arms

  • Experimental
    Ibuprofen 600 mg ER group

    One-hundred and sixty subjects will be randomly assigned to the Ibuprofen 600 mg ER treatment group based on gender and baseline pain intensity, as rated on an 11-point numerical rating scale (PI-NRS; 5-7 moderate pain, or 8-10, severe pain).

    Drug: Ibuprofen 600 mg Extended-Release Tablets

  • Placebo comparator
    Placebo group

    Eighty subjects will be randomly assigned to the Placebo treatment group based on gender and baseline pain intensity, as rated on an 11-point numerical rating scale (PI-NRS; 5-7 moderate pain, or 8-10, severe pain).

    Drug: Placebo

Interventions

  • Ibuprofen 600 mg Extended-Release Tablet: One 600 mg tablet taken orally every 12 hours or twice daily (BID). Each dose was administered with at least 6 ounces of water. Dose 1 was administered at hour 0, Dose 2 was administered at hour 12, Dose 3 was administered at hour 24 and Dose 4 was administered at hour 36.

    Also known as: Ibuprofen 600 mg ER

  • DrugPlacebo

    Placebo: One matching placebo tablet was taken orally every 12 hours or twice daily (BID). Each dose was administered with at least 6 ounces of water. Dose 1 was administered at hour 0, Dose 2 was administered at hour 12, Dose 3 was administered at hour 24 and Dose 4 was administered at hour 36.

07

What researchers measure

Primary outcomes

  1. Analgesic Efficacy, as Measured by the Sum of Pain Intensity Differences (SPID) Scale

    Analgesic efficacy for the 8-12 hour measurement interval after dose 1 using Sum of Pain Intensity Differences (SPID). An 11-point Pain Intensity Numerical Rating Scale (PI-NRS) was used to record pain intensity at baseline and 8, 9, 10, 11, 12 hours after dose 1. The scale went from 0 (no pain) to 10 (Worst possible pain). The outcome measure is based a mean of the sum of each of the five time points evaluated. The total time scale ranges from 0 to 50. Subjects were asked to select the number that best describes how much pain they had at the time of observation.

    Time frame: from baseline to 12 hours after dose 1

  2. Durability of Effect as Measured by the Number of Subjects Achieving Meaningful Improvement in Pain Intensity Difference (PID) From Baseline at All Three Assessment Periods of 24, 36, and 48 Hours

    Response rate measured the durability of effect and was measured by the number of subjects achieving a reduction of at least 2 points (greater than or equal to 20%) from baseline on the 11-point Pain Intensity Numerical Rating Scale (PI-NRS) at all 3 assessment periods of 24, 36 and 48 hours. The scale went from 0 (no pain) to 10 (Worst possible pain). Subjects were asked to select the number that best describes how much pain they had at the time of observation.

    Time frame: 24, 36, and 48 hours

Secondary outcomes

  1. Time to Confirmed "First Perceptible" Relief

    When the subject was administered study medication at Time 0, the Study Coordinator started 2 stopwatches. In an effort to determine the exact moment that the subject began to obtain noticeable pain relief, the subject was instructed to stop the stopwatch when "initial" relief was observed and again when "meaningful" relief was achieved. Time to confirmed first perceptible relief was defined as the time to first perceptible relief, provided that the subject also later stopped the second stopwatch indicating meaningful relief. The assigned censored time for "No Pain Relief" is 240 minutes.

    Time frame: Within 4 hours post Dose 1

  2. Time to Confirmed "Meaningful" Relief

    When the subject was administered study medication at Time 0, the Study Coordinator started 2 stopwatches. To determine the exact moment that the subject began to notice pain relief, the subject was instructed to stop the stopwatch when "initial" relief was observed and again when "meaningful" relief was achieved. Time to confirmed "meaningful" relief was achieved if both stopwatches were stopped within the 4 hour observation period, when both "initial" and "meaningful" relief were observed. Meaningful relief is a subjective definition, based on each subjects determination of pain.

    Time frame: Within 4 hours post Dose 1

  3. Percentage (%) of Subjects With Confirmed First Perceptible Relief Within 1 Hour of Dose 1

    Percentage (percentage of total) of subjects with "first perceptible" relief within 1 hour of Dose 1. The assigned censored time for "No Pain Relief" was 240 minutes.

    Time frame: Within 1 hour of Dose 1

  4. Percentage of Subjects Achieving "Meaningful" Relief as Indicated by the Time Recorded on the Second Stopwatch Following "First Perceptible" Relief

    Percentage(%) of subjects with confirmed first perceptible relief and meaningful relief after dose 1. Subjects that achieved both "first perceptible" relief and "meaningful" relief within the time allotted. The assigned censored time for "No Pain Relief" is 240 minutes. Meaningful relief is a subjective definition, based on each subject's determination of pain

    Time frame: Within 4 hours post Dose 1

  5. Analgesic Efficacy for the 0-12, 0-4, 4-8, and 4-12 Hour Dosing Intervals After Dose 1 Using Total Pain Relief (TOTPAR) and Sum of Pain Intensity Difference(SPID)

    The Pain Intensity Difference (PID) at each time point was derived by subtracting the pain intensity from baseline pain intensity, so that a higher value was indicative of a greater improvement. Time weighted SPID for each specified interval (scale ranges from 0 to 10; 0=no pain relief and 10= complete pain relief) was derived by first multiplying each PID score by the time from the previous time point, and adding them together for each scheduled time point within the time interval (e.g., 4-12 hours in case of SPID 4-12). Time weighted TOTPAR for each specified interval was similarly derived.

    Time frame: 0-12 hours after Dose 1

  6. Duration of Relief After Dose 1

    Duration of relief was defined as the time to treatment failure (i.e.,taking rescue medication, or withdrawing due to lack of efficacy) up to the 12-hour time point. For those withdrawing from the study due to lack of efficacy prior to taking dose 2 or rescue medication, time to treatment failure was the time from dose 1 to the last assesment time. For those discontinuing from the study for any other reason, the time to treatment failure was censored at the last assessment time.

    Time frame: Time to rescue or time of Dose 2 (up to 12 hours following dose 1)

  7. Percentage of Participants Who Require Rescue Medication at or Prior to Hour 8, Hour 10, and Hour 12 After Taking Dose 1

    Percentage of participants who require rescue medication (Lortab) at or prior to hour 8, hour 10 and hour 12 were reported and 95% confidence intervals for the corresponding parameters were calculated.

    Time frame: 0-12 hours after taking Dose 1

  8. Pain Relief and PID Scores at Individual Time Points for Dose 1

    Pain relief and pain intensity difference (PID) scores at individual time points were summarized by descriptive statistics. The PID at each time point prior to dose 2 was derived by subtracting the pain intensity from the baseline pain intensity, so that a higher value was indicative of a greater improvement. Range of possible scores could be from 0 (no improvement) to 5 (greatest possible improvement)

    Time frame: 24, 36, 48 hours after taking Dose 1

  9. Global Evaluation for Dose 1

    Global evaluation for dose 1, either at the time of rescue or at dose 2 (hour 12), whichever came first were summarized. At the 12-hour time point but before Dose 2, or within 1 minute of rescue medication use (if it occurred before hour 12), the subject was to provide a Global Evaluation of Dose 1 of study medication on an 11 point PI-NRS in response to the following command: "Select the number that best describes how you would rate this medication as a pain-reliever (select one number only)." The range went from 0 (Very poor) to 10 (Excellent).

    Time frame: At 12 hours after Dose 1 or at time of rescue

  10. Global Evaluation, Maximum Relief, and Overall Relief for Dose 2

    Global evaluation, maximum relief, and overall relief scores for dose 2 were summarized with descriptive statistics. The subject was to provide a description for the Global Evaluation, maximum relief and overall relief of Dose 2 of study medication on an 11 point PI-NRS: Global Evaluation: "rate the study medication as a pain-reliever"; Maximum Pain Relief: "maximum pain relief received from the last dose"; Overall Pain Relief: "overall quantity of pain relief received from the last dose". The range went from 0 (Very poor or No relief) to 10 (Excellent or Complete relief).

    Time frame: At 24 hours or at time of rescue between 12 and 24 hours

  11. Global Evaluation, Maximum Relief, and Overall Relief for Dose 3

    Global evaluation, maximum relief, and overall relief scores for dose 3 were summarized with descriptive statistics. The subject was to provide a description for the Global Evaluation, maximum relief and overall relief of Dose 3 of study medication on an 11 point PI-NRS: Global Evaluation: "rate the study medication as a pain-reliever"; Maximum Pain Relief: "maximum pain relief received from the last dose"; Overall Pain Relief: "overall quantity of pain relief received from the last dose". The range went from 0 (Very poor or No relief) to 10 (Excellent or Complete relief).

    Time frame: At 36 hours or at time rescue between 24 and 36 hours

  12. Global Evaluation, Maximum Relief, and Overall Relief for Dose 4

    Global evaluation, maximum relief, and overall relief scores for dose 4 were summarized with descriptive statistics. The subject was to provide a description for the Global Evaluation, maximum relief and overall relief of Dose 4 of study medication on an 11 point PI-NRS: Global Evaluation: "rate the study medication as a pain-reliever"; Maximum Pain Relief: "maximum pain relief received from the last dose"; Overall Pain Relief: "overall quantity of pain relief received from the last dose". The range went from 0 (Very poor or No relief) to 10 (Excellent or Complete relief).

    Time frame: At 48 hours or at time of rescue between 36 and 48 hours.

08

Results

Posted Mar 23, 2011
Limitations and caveats
Of the 12 subjects who prematurely discontinued all 4 doses of the study drug, 6 subjects received 1 dose of study drug, 2 subjects received 2 doses, and 4 subjects received 3 doses.

Participant flow

Date First Subject Enrolled: 24 June 2008 Date Last Subject Enrolled: 11 October 2008 All subjects were to receive 4 doses of study drug or placebo at 12-hour intervals. Of the 12 subjects who prematurely discontinued study drug, 6 subjects received 1 dose of study drug, 2 subjects received 2 doses, and 4 subjects received 3 doses.

Participant flow — Overall Study
MilestoneIbuprofen 600mg ERPlacebo
Started16987
Completed16183
Not completed84
Withdrew: Withdrawal by subject83
Withdrew: Dosed incorrectly01

Outcome measures

PrimaryAnalgesic Efficacy, as Measured by the Sum of Pain Intensity Differences (SPID) Scale

Analgesic efficacy for the 8-12 hour measurement interval after dose 1 using Sum of Pain Intensity Differences (SPID). An 11-point Pain Intensity Numerical Rating Scale (PI-NRS) was used to record pain intensity at baseline and 8, 9, 10, 11, 12 hours after dose 1. The scale went from 0 (no pain) to 10 (Worst possible pain). The outcome measure is based a mean of the sum of each of the five time points evaluated. The total time scale ranges from 0 to 50. Subjects were asked to select the number that best describes how much pain they had at the time of observation.

Time frame:
from baseline to 12 hours after dose 1
Reported as:
Mean · Units on a scale
Analgesic Efficacy, as Measured by the Sum of Pain Intensity Differences (SPID) Scale
Units on a scaleIbuprofen 600mg ERPlacebo
Analgesic Efficacy, as Measured by the Sum of Pain Intensity Differences (SPID) Scale14.80 ± 16.3310.40 ± 11.933
Statistical analysis
  • Ibuprofen 600mg ER vs Placebo · ANCOVA · p = <0.0001
PrimaryDurability of Effect as Measured by the Number of Subjects Achieving Meaningful Improvement in Pain Intensity Difference (PID) From Baseline at All Three Assessment Periods of 24, 36, and 48 Hours

Response rate measured the durability of effect and was measured by the number of subjects achieving a reduction of at least 2 points (greater than or equal to 20%) from baseline on the 11-point Pain Intensity Numerical Rating Scale (PI-NRS) at all 3 assessment periods of 24, 36 and 48 hours. The scale went from 0 (no pain) to 10 (Worst possible pain). Subjects were asked to select the number that best describes how much pain they had at the time of observation.

Time frame:
24, 36, and 48 hours
Reported as:
Number · participants
Durability of Effect as Measured by the Number of Subjects Achieving Meaningful Improvement in Pain Intensity Difference (PID) From Baseline at All Three Assessment Periods of 24, 36, and 48 Hours
participantsIbuprofen 600mg ERPlacebo
Durability of Effect as Measured by the Number of Subjects Achieving Meaningful Improvement in Pain Intensity Difference (PID) From Baseline at All Three Assessment Periods of 24, 36, and 48 Hours12347
Statistical analysis
  • Ibuprofen 600mg ER vs Placebo · ANCOVA · p = <0.0017
SecondaryTime to Confirmed "First Perceptible" Relief

When the subject was administered study medication at Time 0, the Study Coordinator started 2 stopwatches. In an effort to determine the exact moment that the subject began to obtain noticeable pain relief, the subject was instructed to stop the stopwatch when "initial" relief was observed and again when "meaningful" relief was achieved. Time to confirmed first perceptible relief was defined as the time to first perceptible relief, provided that the subject also later stopped the second stopwatch indicating meaningful relief. The assigned censored time for "No Pain Relief" is 240 minutes.

Time frame:
Within 4 hours post Dose 1
Reported as:
Median · Minutes
Time to Confirmed "First Perceptible" Relief
MinutesIbuprofen 600mg ERPlacebo
Time to Confirmed "First Perceptible" Relief42.00 (4 to 81)240 (240 to 240)
Statistical analysis
  • Ibuprofen 600mg ER vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001
SecondaryTime to Confirmed "Meaningful" Relief

When the subject was administered study medication at Time 0, the Study Coordinator started 2 stopwatches. To determine the exact moment that the subject began to notice pain relief, the subject was instructed to stop the stopwatch when "initial" relief was observed and again when "meaningful" relief was achieved. Time to confirmed "meaningful" relief was achieved if both stopwatches were stopped within the 4 hour observation period, when both "initial" and "meaningful" relief were observed. Meaningful relief is a subjective definition, based on each subjects determination of pain.

Time frame:
Within 4 hours post Dose 1
Reported as:
Median · Minutes
Time to Confirmed "Meaningful" Relief
MinutesIbuprofen 600mg ERPlacebo
Time to Confirmed "Meaningful" Relief108 (18 to 240)240 (240 to 240)
Statistical analysis
  • Ibuprofen 600mg ER vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001
SecondaryPercentage (%) of Subjects With Confirmed First Perceptible Relief Within 1 Hour of Dose 1

Percentage (percentage of total) of subjects with "first perceptible" relief within 1 hour of Dose 1. The assigned censored time for "No Pain Relief" was 240 minutes.

Time frame:
Within 1 hour of Dose 1
Reported as:
Number · Percent of participants
Percentage (%) of Subjects With Confirmed First Perceptible Relief Within 1 Hour of Dose 1
Percent of participantsIbuprofen 600mg ERPlacebo
Percentage (%) of Subjects With Confirmed First Perceptible Relief Within 1 Hour of Dose 162 (54 to 69)12 (5 to 18)
Statistical analysis
  • Ibuprofen 600mg ER vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001
SecondaryPercentage of Subjects Achieving "Meaningful" Relief as Indicated by the Time Recorded on the Second Stopwatch Following "First Perceptible" Relief

Percentage(%) of subjects with confirmed first perceptible relief and meaningful relief after dose 1. Subjects that achieved both "first perceptible" relief and "meaningful" relief within the time allotted. The assigned censored time for "No Pain Relief" is 240 minutes. Meaningful relief is a subjective definition, based on each subject's determination of pain

Time frame:
Within 4 hours post Dose 1
Reported as:
Number · Percent of participants
Percentage of Subjects Achieving "Meaningful" Relief as Indicated by the Time Recorded on the Second Stopwatch Following "First Perceptible" Relief
Percent of participantsIbuprofen 600mg ERPlacebo
Percentage of Subjects Achieving "Meaningful" Relief as Indicated by the Time Recorded on the Second Stopwatch Following "First Perceptible" Relief69 (62 to 76)17 (9 to 25)
Statistical analysis
  • Ibuprofen 600mg ER vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001
  • Ibuprofen 600mg ER vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (Estimated Confidence Interval: 95%Method: Cochran-Mantel-Haenszel)
SecondaryAnalgesic Efficacy for the 0-12, 0-4, 4-8, and 4-12 Hour Dosing Intervals After Dose 1 Using Total Pain Relief (TOTPAR) and Sum of Pain Intensity Difference(SPID)

The Pain Intensity Difference (PID) at each time point was derived by subtracting the pain intensity from baseline pain intensity, so that a higher value was indicative of a greater improvement. Time weighted SPID for each specified interval (scale ranges from 0 to 10; 0=no pain relief and 10= complete pain relief) was derived by first multiplying each PID score by the time from the previous time point, and adding them together for each scheduled time point within the time interval (e.g., 4-12 hours in case of SPID 4-12). Time weighted TOTPAR for each specified interval was similarly derived.

Time frame:
0-12 hours after Dose 1
Reported as:
Mean · Time weighted units on a scale
Analgesic Efficacy for the 0-12, 0-4, 4-8, and 4-12 Hour Dosing Intervals After Dose 1 Using Total Pain Relief (TOTPAR) and Sum of Pain Intensity Difference(SPID)
Time weighted units on a scaleIbuprofen 600mg ERPlacebo
TOTPAR 0-12 hours54.59 ± 40.83012.05 ± 27.114
TOTPAR 0-4 hours16.84 ± 11.8543.18 ± 6.749
TOTPAR 4-8 hours25.94 ± 19.0135.34 ± 12.393
TOTPAR 4-12 hours43.38 ± 33.8519.92 ± 23.411
SPID 0-12 hours37.20 ± 34.7910.45 ± 24.378
SPID 0-4 hours11.64 ± 10.222-0.18 ± 6.591
SPID 4-8 hours17.88 ± 16.1580.24 ± 11.034
SPID 4-12 hours29.49 ± 28.6540.67 ± 20.617
Statistical analysis
  • Ibuprofen 600mg ER vs Placebo · ANCOVA · p = <0.0001With terms for treatment, gender, and baseline pain score categories stratified as ≤7 and \>7.
SecondaryDuration of Relief After Dose 1

Duration of relief was defined as the time to treatment failure (i.e.,taking rescue medication, or withdrawing due to lack of efficacy) up to the 12-hour time point. For those withdrawing from the study due to lack of efficacy prior to taking dose 2 or rescue medication, time to treatment failure was the time from dose 1 to the last assesment time. For those discontinuing from the study for any other reason, the time to treatment failure was censored at the last assessment time.

Time frame:
Time to rescue or time of Dose 2 (up to 12 hours following dose 1)
Reported as:
Median · Minutes
Duration of Relief After Dose 1
MinutesIbuprofen 600mg ERPlacebo
Duration of Relief After Dose 1720 (1 to 720)101 (1 to 720)
Statistical analysis
  • Ibuprofen 600mg ER vs Placebo · Log Rank · p = <0.0001
SecondaryPercentage of Participants Who Require Rescue Medication at or Prior to Hour 8, Hour 10, and Hour 12 After Taking Dose 1

Percentage of participants who require rescue medication (Lortab) at or prior to hour 8, hour 10 and hour 12 were reported and 95% confidence intervals for the corresponding parameters were calculated.

Time frame:
0-12 hours after taking Dose 1
Reported as:
Least squares mean · Percentage of participants
Percentage of Participants Who Require Rescue Medication at or Prior to Hour 8, Hour 10, and Hour 12 After Taking Dose 1
Percentage of participantsIbuprofen 600mg ERPlacebo
Rescue at or prior to 8 hours after dose 131.4 (24 to 38)82.8 (75 to 91)
Rescue at or prior to 10 hours after dose 134.9 (28 to 42)85.1 (78 to 93)
Rescue at or prior to 12 hours after dose 136.1 (29 to 43)85.1 (78 to 93)
Statistical analysis
  • Ibuprofen 600mg ER vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001
SecondaryPain Relief and PID Scores at Individual Time Points for Dose 1

Pain relief and pain intensity difference (PID) scores at individual time points were summarized by descriptive statistics. The PID at each time point prior to dose 2 was derived by subtracting the pain intensity from the baseline pain intensity, so that a higher value was indicative of a greater improvement. Range of possible scores could be from 0 (no improvement) to 5 (greatest possible improvement)

Time frame:
24, 36, 48 hours after taking Dose 1
Reported as:
Mean · Units on a scale
Pain Relief and PID Scores at Individual Time Points for Dose 1
Units on a scaleIbuprofen 600mg ERPlacebo
24 hours after dose 1.3.11 ± 3.4660.18 ± 2.599
36 hours after dose 1.3.10 ± 3.4600.22 ± 2.704
48 hours after dose 1.3.44 ± 3.7560.22 ± 2.721
Statistical analysis
  • Ibuprofen 600mg ER vs Placebo · ANCOVA · p = <0.0001
SecondaryGlobal Evaluation for Dose 1

Global evaluation for dose 1, either at the time of rescue or at dose 2 (hour 12), whichever came first were summarized. At the 12-hour time point but before Dose 2, or within 1 minute of rescue medication use (if it occurred before hour 12), the subject was to provide a Global Evaluation of Dose 1 of study medication on an 11 point PI-NRS in response to the following command: "Select the number that best describes how you would rate this medication as a pain-reliever (select one number only)." The range went from 0 (Very poor) to 10 (Excellent).

Time frame:
At 12 hours after Dose 1 or at time of rescue
Reported as:
Mean · Units on a scale
Global Evaluation for Dose 1
Units on a scaleIbuprofen 600mg ERPlacebo
Global Evaluation for Dose 16.05 ± 3.5361.79 ± 2.898
Statistical analysis
  • Ibuprofen 600mg ER vs Placebo · ANCOVA · p = <0.0001 (P-value from ANCOVA with terms for treatment, gender and baseline pain score categories.)
SecondaryGlobal Evaluation, Maximum Relief, and Overall Relief for Dose 2

Global evaluation, maximum relief, and overall relief scores for dose 2 were summarized with descriptive statistics. The subject was to provide a description for the Global Evaluation, maximum relief and overall relief of Dose 2 of study medication on an 11 point PI-NRS: Global Evaluation: "rate the study medication as a pain-reliever"; Maximum Pain Relief: "maximum pain relief received from the last dose"; Overall Pain Relief: "overall quantity of pain relief received from the last dose". The range went from 0 (Very poor or No relief) to 10 (Excellent or Complete relief).

Time frame:
At 24 hours or at time of rescue between 12 and 24 hours
Reported as:
Mean · Units on a scale
Global Evaluation, Maximum Relief, and Overall Relief for Dose 2
Units on a scaleIbuprofen 600mg ERPlacebo
Global Evalution for Dose 26.82 ± 2.9144.24 ± 3.673
Maximum Relief for Dose 27.27 ± 2.9975.02 ± 3.864
Overall Relief for Dose 26.62 ± 3.0054.46 ± 3.588
Statistical analysis
  • Ibuprofen 600mg ER vs Placebo · ANCOVA · p = <0.0001 (P- value from ANCOVA with terms for treatment, gender and baseline pain score categories.)
  • Ibuprofen 600mg ER vs Placebo · ANCOVA · p = <0.0001 (P-value from ANCOVA with terms for treatment, gender and baseline pain scores categories.)
  • Ibuprofen 600mg ER vs Placebo · ANCOVA · p = <0.0001 (P-value from ANCOVA with terms for treatment, gender and baseline pain score categories.)
SecondaryGlobal Evaluation, Maximum Relief, and Overall Relief for Dose 3

Global evaluation, maximum relief, and overall relief scores for dose 3 were summarized with descriptive statistics. The subject was to provide a description for the Global Evaluation, maximum relief and overall relief of Dose 3 of study medication on an 11 point PI-NRS: Global Evaluation: "rate the study medication as a pain-reliever"; Maximum Pain Relief: "maximum pain relief received from the last dose"; Overall Pain Relief: "overall quantity of pain relief received from the last dose". The range went from 0 (Very poor or No relief) to 10 (Excellent or Complete relief).

Time frame:
At 36 hours or at time rescue between 24 and 36 hours
Reported as:
Mean · Units on a scale
Global Evaluation, Maximum Relief, and Overall Relief for Dose 3
Units on a scaleIbuprofen 600mg ERPlacebo
Global Evaluation for Dose 37.14 ± 2.8394.98 ± 3.549
Maximum Relief for Dose 37.61 ± 2.9225.63 ± 3.805
Overall Relief for Dose 36.76 ± 2.9425.02 ± 3.634
Statistical analysis
  • Ibuprofen 600mg ER vs Placebo · ANCOVA · p = <0.0001 (P-value from ANCOVA with terms for treatment, gender and baseline pain score categories.)
  • Ibuprofen 600mg ER vs Placebo · ANCOVA · p = <0.0001 (P-value from ANCOVA with terms for treatment, gender and basee pain score categories.)
  • Ibuprofen 600mg ER vs Placebo · ANCOVA · p = <0.0001 (P-value from ANCOVA with terms for treatment, gender and baseline pain score categories.)
SecondaryGlobal Evaluation, Maximum Relief, and Overall Relief for Dose 4

Global evaluation, maximum relief, and overall relief scores for dose 4 were summarized with descriptive statistics. The subject was to provide a description for the Global Evaluation, maximum relief and overall relief of Dose 4 of study medication on an 11 point PI-NRS: Global Evaluation: "rate the study medication as a pain-reliever"; Maximum Pain Relief: "maximum pain relief received from the last dose"; Overall Pain Relief: "overall quantity of pain relief received from the last dose". The range went from 0 (Very poor or No relief) to 10 (Excellent or Complete relief).

Time frame:
At 48 hours or at time of rescue between 36 and 48 hours.
Reported as:
Mean · Units on a scale
Global Evaluation, Maximum Relief, and Overall Relief for Dose 4
Units on a scaleIbuprofen 600mg ERPlacebo
Global Evalution for Dose 47.26 ± 2.9534.70 ± 3.715
Maximum Relief for Dose 47.66 ± 2.9705.34 ± 3.970
Overall Relief for Dose 47.06 ± 3.0454.89 ± 3.803
Statistical analysis
  • Ibuprofen 600mg ER vs Placebo · ANCOVA · p = <0.0001 (P-value from ANCOVA with terms for treatment, gender and baseline pain score categories.)
  • Ibuprofen 600mg ER vs Placebo · ANCOVA · p = <0.0001 (P-value from ANCOVA with terms for treatment, gender and baseline pain score categories.)
  • Ibuprofen 600mg ER vs Placebo · ANCOVA · p = <0.0001 (P-value from ANCOVA with terms for treatment, gender and baseline pain score categories.)

Adverse events

Non-serious events are listed at a 0.35% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ibuprofen 600mg ER—0/169 (0%)0/169 (0%)
Placebo—0/87 (0%)0/87 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Ibuprofen 600mg ERPlaceboTotal
<=18 years643599
Between 18 and 65 years10552157
>=65 years000
Age Continuous
Age Continuous(years)Ibuprofen 600mg ERPlaceboTotal
Mean18.9 ± 3.2218.8 ± 3.2518.9 ± 3.22
Sex: Female, Male
Sex: Female, Male(Participants)Ibuprofen 600mg ERPlaceboTotal
Female9547142
Male7440114
Region of Enrollment
Region of Enrollment(participants)Ibuprofen 600mg ERPlaceboTotal
United States16987256
09

Study locations

1 site
  • Jean Brown Research
    Salt Lake City, Utah 84124, United States
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2008, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2011, 2 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2008
First posted
Jun 30, 2008
Start
Jun 2008
Primary completionActual
Oct 2008
CompletionActual
Oct 2008
Results first posted
Mar 23, 2011
Last update
Mar 24, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00707057
Lead sponsor
SCOLR Pharma, Inc.
Collaborators
AAIPharma, Jean Brown Research
First posted
Jun 30, 2008
Start date
Jun 2008
Primary completion
Oct 2008
Completion
Oct 2008
Results posted
Mar 23, 2011
Last update
Mar 24, 2011

Study contacts

Steven E Christensen, D.D.S.
principal investigator · Jean Brown Research

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibuprofen

Start the discussion